Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trials - PubMed (original) (raw)
. 2015 Nov;2(11):e492-502.
doi: 10.1016/S2352-3026(15)00153-2. Epub 2015 Oct 22.
Francesco Giusti 2, Ivan R Vogelius 3, Michael Lundemann 4, Marleen A E van der Kaaij 5, Safaa Ramadan 6, Bart Meulemans 2, Michel Henry-Amar 7, Berthe M P Aleman 8, John Raemaekers 9, Paul Meijnders 10, Elisabeth C Moser 11, Hanneke C Kluin-Nelemans 12, Pierre Feugier 13, Olivier Casasnovas 14, Catherine Fortpied 2, Lena Specht 15; European Organisation for Research and Treatment of Cancer (EORTC) Lymphoma Group
Affiliations
- PMID: 26686259
- DOI: 10.1016/S2352-3026(15)00153-2
Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trials
Maja V Maraldo et al. Lancet Haematol. 2015 Nov.
Abstract
Background: Cardiovascular disease after treatment is an important concern in cancer survivors. However, knowledge of cardiotoxicity is limited by the retrospective nature of data, which often does not contain details of treatment exposure. To facilitate individual risk counselling of patients, we aimed to quantify the effect of anthracyclines, vinca-alkaloids, and radiotherapy on the risk of cardiovascular disease in patients treated for Hodgkin's lymphoma.
Methods: In 2009-10, a Life Situation Questionnaire (LSQ) was distributed to patients by mail to assess late-onset effects of Hodgkin's lymphoma treatment in patients who were included in nine successive European Organisation for Research and Treatment of Cancer (EORTC) and the Groupe d'Etude des Lymphomes de l'Adulte (GELA, now renamed LYSA) randomised trials between 1964 and 2004. We reconstructed the mean radiation doses to the heart and carotid arteries and the cumulative doses of anthracyclines and vinca-alkaloids for all patients. Incidence of cardiovascular disease was reported during follow-up and updated through the LSQ. We applied Cox proportional hazards regression analyses to quantify the effect of chemotherapy and radiation on the risk of a first cardiovascular disease event.
Findings: Information of primary treatment was complete for 6039 patients (median age at diagnosis 30 years [IQR 23-40]; median length of follow-up 9 years [6-14]). 1919 patients responded to the LSQ. 1238 first cardiovascular events were recorded in 703 patients, most were ischaemic heart disease (132 [19%]), congestive heart failure (85 [12%]), arrhythmia (110 [16%]), and valvular disease (77 [11%]). The mean heart radiation dose per 1 Gy increase (HR 1·015 [95% CI 1·006-1·024], p=0·0014) and the dose of anthracyclines per 50 mg/m(2) increase in cumulative dose (1·077 [1·021-1·137], p=0·0064) were significant predictors of cardiovascular disease. Cumulative dose of vinblastine (unadjusted model p=0·77), vincristine (p=0·36), and mean radiation dose to the left (p=0·41) or right (p=0·70) internal carotid artery did not predict for cardiovascular events.
Interpretation: Quantification of the increased cardiovascular risk with specific doses of radiation and anthracycline exposure will enable a quantitative assessment of the optimum combination of systemic therapy and radiation, which will help clinicians to balance the risks and benefits of different regimens for individual patients.
Funding: Rigshospitalet Research Committee, the EORTC Cancer Research Fund, and the Sally Snowman Survivorship Fellowship.
Copyright © 2015 Elsevier Ltd. All rights reserved.
Comment in
- Cardiovascular disease after Hodgkin's lymphoma: a role for screening.
Kupeli S. Kupeli S. Lancet Haematol. 2015 Nov;2(11):e461-2. doi: 10.1016/S2352-3026(15)00194-5. Epub 2015 Oct 22. Lancet Haematol. 2015. PMID: 26686254 No abstract available.
Similar articles
- Premature ovarian failure and fertility in long-term survivors of Hodgkin's lymphoma: a European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d'Etude des Lymphomes de l'Adulte Cohort Study.
van der Kaaij MA, Heutte N, Meijnders P, Abeilard-Lemoisson E, Spina M, Moser EC, Allgeier A, Meulemans B, Simons AH, Lugtenburg PJ, Aleman BM, Noordijk EM, Fermé C, Thomas J, Stamatoullas A, Fruchart C, Brice P, Gaillard I, Bologna S, Ong F, Eghbali H, Doorduijn JK, Morschhauser F, Sebban C, Roesink JM, Bouteloup M, Van Hoof A, Raemaekers JM, Henry-Amar M, Kluin-Nelemans HC. van der Kaaij MA, et al. J Clin Oncol. 2012 Jan 20;30(3):291-9. doi: 10.1200/JCO.2011.37.1989. Epub 2011 Dec 19. J Clin Oncol. 2012. PMID: 22184372 - Cumulative burden of cardiovascular morbidity in paediatric, adolescent, and young adult survivors of Hodgkin's lymphoma: an analysis from the St Jude Lifetime Cohort Study.
Bhakta N, Liu Q, Yeo F, Baassiri M, Ehrhardt MJ, Srivastava DK, Metzger ML, Krasin MJ, Ness KK, Hudson MM, Yasui Y, Robison LL. Bhakta N, et al. Lancet Oncol. 2016 Sep;17(9):1325-34. doi: 10.1016/S1470-2045(16)30215-7. Epub 2016 Jul 25. Lancet Oncol. 2016. PMID: 27470081 Free PMC article. - Gonadal function in males after chemotherapy for early-stage Hodgkin's lymphoma treated in four subsequent trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d'Etude des Lymphomes de l'Adulte.
van der Kaaij MA, Heutte N, Le Stang N, Raemaekers JM, Simons AH, Carde P, Noordijk EM, Fermé C, Thomas J, Eghbali H, Kluin-Nelemans HC, Henry-Amar M; European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group; Groupe d'Etude des Lymphomes de l'Adulte. van der Kaaij MA, et al. J Clin Oncol. 2007 Jul 1;25(19):2825-32. doi: 10.1200/JCO.2006.10.2020. Epub 2007 May 21. J Clin Oncol. 2007. PMID: 17515571 Clinical Trial. - Long-term risk of second malignancy and cardiovascular disease after Hodgkin lymphoma treatment.
van Leeuwen FE, Ng AK. van Leeuwen FE, et al. Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):323-330. doi: 10.1182/asheducation-2016.1.323. Hematology Am Soc Hematol Educ Program. 2016. PMID: 27913498 Free PMC article. Review.
Cited by
- A Historical Survey of Key Epidemiological Studies of Ionizing Radiation Exposure.
Little MP, Bazyka D, Berrington de Gonzalez A, Brenner AV, Chumak VV, Cullings HM, Daniels RD, French B, Grant E, Hamada N, Hauptmann M, Kendall GM, Laurier D, Lee C, Lee WJ, Linet MS, Mabuchi K, Morton LM, Muirhead CR, Preston DL, Rajaraman P, Richardson DB, Sakata R, Samet JM, Simon SL, Sugiyama H, Wakeford R, Zablotska LB. Little MP, et al. Radiat Res. 2024 Aug 1;202(2):432-487. doi: 10.1667/RADE-24-00021.1. Radiat Res. 2024. PMID: 39021204 Review. - Postoperative radiotherapy does not improve survival in patients with Masaoka-Koga stage IIB thymomas: A propensity score matching study based on the SEER database.
Shi Y, Chen H, Luo S, Xiong J, Xiong L, Yu D. Shi Y, et al. Medicine (Baltimore). 2024 May 10;103(19):e37956. doi: 10.1097/MD.0000000000037956. Medicine (Baltimore). 2024. PMID: 38728510 Free PMC article. - How I Follow Hodgkin Lymphoma in First Complete (Metabolic) Remission?
Milunović V. Milunović V. Medicina (Kaunas). 2024 Feb 19;60(2):344. doi: 10.3390/medicina60020344. Medicina (Kaunas). 2024. PMID: 38399631 Free PMC article. Review. - Harnessing multi-source data for individualized care in Hodgkin Lymphoma.
Parsons SK, Rodday AM, Upshaw JN, Scharman CD, Cui Z, Cao Y, Tiger YKR, Maurer MJ, Evens AM. Parsons SK, et al. Blood Rev. 2024 May;65:101170. doi: 10.1016/j.blre.2024.101170. Epub 2024 Jan 14. Blood Rev. 2024. PMID: 38290895 Review. - Immunotherapy-Associated Atherosclerosis: A Comprehensive Review of Recent Findings and Implications for Future Research.
Chan A, Torelli S, Cheng E, Batchelder R, Waliany S, Neal J, Witteles R, Nguyen P, Cheng P, Zhu H. Chan A, et al. Curr Treat Options Cardiovasc Med. 2023;25(12):715-735. doi: 10.1007/s11936-023-01024-0. Epub 2023 Dec 15. Curr Treat Options Cardiovasc Med. 2023. PMID: 38213548 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical